Summary Recombinant single-chain fragments (scFv) of the murine anti-MUC1 monoclonal antibody C595 have been produced using the original hybridoma cells as a source of variable heavy (VH)-and variable light (VL)-chain-encoding antibody genes. The use of the polymerase chain reaction (PCR), bacteriophage (phage) display technology and gene expression systems in E. coli has led to the production of soluble C595 scFv. The scFv has been purified from the bacterial supernatant by peptide epitope affinity chromatography, leading to the recovery of immunoreactive C595 scFv, which was similar in activity to the C595 parent antibody. Analysis by DNA sequencing, SDS-PAGE and Western blotting has demonstrated the integrity of the scFv, while ELISA, FACScan analysis, fluorescence quenching, quantitative immunoreactivity experiments and immunohistochemistry confirm that the activity of the scFv compares favourably with that of the parent antibody. The retention of binding activity to MUC1 antigen on human bladder and breast carcinoma tissue specimens illustrates the potential application of this novel product as an immunodiagnostic and immunotherapeutic reagent.
MUC I mucins are highly glycosylated glycoproteins expressed on the luminal surfaces of glandular epithelia (Gendler et al, 1991 ; Price and Tendler, 1993) . Apart from their major physiological functions as protective agents and biological lubricants, they are frequently elevated and/or altered in cancer and thus have the potential to be tumour markers. In breast carcinomas, for example, their expression is frequently up-regulated and they may be secreted into the circulation. Determination of the levels of MUC I antigen in the blood has been exploited as a measure of tumour burden, and changing levels reflect the response to therapy (Berruti et al, 1994; Martoni et al, 1995) . Novel determinants on mucins from malignant cells have been evoked as targets for immune manipulation in the cancer patient as they may induce both humoral (Rughetti et al, 1993; Kotera et al, 1994) and cellular (Jerome et al, 1991; Domenech et al, 1995) responses.
The MUCl glycoprotein is a complex molecule with a protein core containing a large domain of variable numbers of a highly conserved 20 amino acid repeat sequence (PDTRPAPGSTAP-PAHGVTSA) (Gendler et al, 1988) . Many murine antibodies reactive with the MUCI mucin have now been produced by immunization with diverse materials, including milk-fat globule membranes, tumour cells and isolated mucin preparations. Most, if not all, anti-MUCI antibodies reactive with the protein core define epitopes of 3, 4 or 5 amino acids within the hydrophilic region APDTRPAP of the 20 amino acid repeat. The antibody C595 is one such antibody. This antibody has been proved to be a reagent of clinical use. It has been used in immunoassays for the measurement of circulating mucin in breast cancer patients Dixon et al, 1993) and has been used for in vivo diagnostic tests in the identification of malignant ovarian tumours by immunoscintigraphy (Symonds et al, 1992; Perkins et al, 1993) . Also, bladder tumours have been detected by gamma camera imaging following intravesical administration of "'In-labelled C595 (Kunkler et al, 1995) .
The present investigation was initiated to produce derivatives of anti-MUCl mucin antibodies that would have the potential for use in tumour targeting. Here, we describe the production of a recombinant antibody fragment based on the variable region of the anti-MUC1 mucin monoclonal antibody C595. Detailed analyses of the scFv confirm that its antigen recognition characteristics are similar to those of the parent antibody so that further diagnostic and therapeutic applications may be considered.
MATERIALS AND METHODS Monoclonal antibody production
Monoclonal antibody, C595 (IgG3, kappa light chain), was prepared by conventional hybridoma technology (Kohler and Milstein, 1975) using spleen cells from a BALB/c mouse immunized against purified MUCI urinary mucin (Price et al, 1990) . The C595 monoclonal antibody has the alternative designation NCRC-48. mRNA extraction C595 hybridoma cells (1 x 107) were harvested by centrifugation (3000 g for 5 min), the supematant removed by gentle aspiration and the cellular pellet vortexed briefly. Total poly(A)+ mRNA was extracted from the pellet using a Dynabeads mRNA Direct Kit (Dynal, Oslo, Norway). The RNA extract was dissolved in 50 ,u of sterile water, quantified and assessed for purity by absorbance determination at 280 and 260 nm (Sambrook et al, 1989 ) and stored at -20°C. 
Primer design
The primers used in the scFv assembly were provided in the RPAS mouse scFv module. Primers used in sequencing reactions and in PCR analyses were prepared using an ABI 394 DNA synthesizer (ABI, Foster City, CA, USA) at the Biopolymer Synthesis and Analysis Unit (BSAU), Department of Biochemistry, University of Nottingham, UK. The primers denoted S1 (5'-CAACGT-GAAAAAATTATTATTCGC-3') and S6 (5'-GTAAATGAATTlTT-CTGTATGAGG-3') were based on the pCANTAB SE vector sequence. The primers denoted II (5'-TGTGCAAGAGATCGG-GATGGTTAC-3') and 12 (5'-ACTACTCCACTGCTGGCAG-TAATA-3') were based on the complementarity-determining region (CDR)-3-encoding DNA sequences of the C595 heavy and light chains respectively .
PCR analysis
A non-suppressor strain of E. coli (HB2151) was infected with the recombinant phage library and infected clones were anlaysed by PCR for the incorporation of C595 scFv-encoding DNA using C595 heavy-and light-chain-specific primers II and I2 and the vector-specific primers S 1 and S6. PCRs were set up using phageinfected HB2151 E. coli colonies as a source of C595 scFvspecific DNA. PCRs were performed in 100,l1 aliquots using scFv expression Induction of scFv expression was achieved using the lacZ promoter of the pCANTAB 5E vector by the addition of isopropyl beta-D-thiogalactopyranoside (IPTG) substrate into SB medium supplemented with 100 jg ml-' ampicillin (Sambrook et al, 1989) .
A total of 800 ml of substrate was added. Clone 31 was chosen for scFv production on this scale, as preliminary SDS-PAGE and Western blot analyses using 50 ml of substrate had identified this clone as the highest expressor of scFv.
C595 scFv clone 31 purification Recombinant C595 scFv clone 31 was recovered from the supernatant of the bacterial broth, which was centrifuged at 48 000 g for 1 h. The supernatant was decanted through Whatman no. 1 filter paper, sodium azide was added to 0.02% (w/v) and the supernatant was processed through a 0.2-jm, 500-ml bottle filter unit (Costar, High Wycombe, UK). The supernatant was then applied to a peptide epitope affinity column consisting of Sepharose 4B (Pharmacia) conjugated to the peptide APDTRPAPG . This conjugate contains the epitope (RPAP) recognized by the antibody C595, thus only immunoreactive scFv will bind to this column. The column was washed by the addition of phosphatebuffered saline (PBS) containing 0.02% (w/v) sodium azide and then connected to a G25 Sephadex desalting column. Elution of the bound scFv was performed by the application of 3 M sodium thiocyanate. Purified scFv concentrations in the eluent were determined spectrophotometrically at 280 nm using the Beer-Lambert law.
Analysis of scFv clones by sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting Affinity-purified C595 scFv clone 31 samples were diluted 1:1 with SDS loading buffer [bromophenol blue (0.05% w/v), sucrose (40% w/v), EDTA (0.1 M, pH 8.0) and SDS (0.5% w/v)] and pretreated by boiling for 5 min before loading. SDS-PAGE was performed using a PhastSystem Separation and Control Unit (Pharmacia) in conjunction with PhastGel precast gels (homogeneous acrylamide, 12.5% w/v). Silver staining was performed using the PhastGel silver staining kit on the PhastSystem Development Unit. 1:4 methanol-water). After transfer, the membrane was incubated for 1 h in 0.1% casein (w/v) in PBS to block non-specific binding sites. After four washes with PBS, the membrane was incubated with a 1:1000 solution of anti-E-Tag/horseradish peroxidase (HRPO) conjugate (Pharmacia) in PBS for 1 h. After four washes with PBS, the blot was developed using 3-amino-9-ethylcarbazole in 50 mm sodium acetate buffer pH 5.5, with the addition of hydrogen peroxide at 5 ,l ml-' (3-AEC substrate).
DNA sequencing analysis
The clone containing C595-encoding DNA and expressing the scFv as identified by Western blot (clone 31) was further analysed through DNA sequencing. This clone was grown overnight and plasmid (phagemid) DNA extracted using a Hybaid Recovery Kit (Hybaid), essentially using protocols of plasmid minipreparation as outlined in Sambrook et al (1989) . Sequencing reactions were performed on an ABI 373A DNA Sequencer (ABI) using the PRISM DyeDeoxy Terminator Cycle Sequencing Kit (ABI) and I1, 12, S1 and S6 primers.
Immunoreactivity by enzyme-linked immunosorbant assay (ELISA)
Microtitre plates (96-well, flat bottomed, Falcon 3912; Becton Dickinson, Oxford, UK) were coated with affinity-purified urinary mucin (Price et al, 1990) or with branched chain polylysine conjugate containing multiple copies of the peptide CAPDTRPAPG (Hudecz and Price, 1992 ) (added at 50 ,l per well at 10 jig ml-' and incubated for 37°C for 18 h). A negative control antigen was coated to the wells in the same manner. This consisted of a MUC2-related peptide (TPTGTQTPTT) conjugated to bovine serum albumin (BSA). The wells were washed four times with PBS (pH 7.3) containing 0.05% (w/v) Tween 20 (PBS/Tween), and the remaining non-specific sites were blocked by the addition of 1% BSA for 1 h. After four washes in PBS/Tween, semi-logarithmic serial dilutions of C595 scFv (75 jig ml-') were added at 50 jil per well and incubated for 1 h. The plates were again washed four times and anti-E-tag/HRPO (Pharmacia) at 1:1000 in PBS was added, 50 jil per well, and incubated for 1 h. The plates were washed four times in PBS/Tween. A solution of 0.033% (w/v) 2,2'-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid) in 0.1 M citrate phosphate buffer pH 4.0, with 33% (v/v) hydrogen peroxide added at 0.3 jil ml-' (ABTS substrate) was added to the wells at 100 jil per well. Analysis of colour development was performed over a 10 min period using a Milenia Kinetic Analyser (Diagnostic Products Corporation, Llanberis, UK).
Flow cytometry Breast carcinoma T47D cells were grown in RPMI 1640 medium in 75-cm3 tissue culture-treated flasks (Falcon) supplemented with 2 mM L-glutamine and 10% heat-inactivated fetal bovine serum. Adherent cells were grown to subconfluence and harvested after incubation with 0.05% (w/v) trypsin/0.02% (w/v) EDTA at 37°C. Cells (1 x 105 cells per sample in duplicate) were transferred to a 1.5-ml Eppendorf tube and centrifuged at 10 000 g for 30 s. The supernatant was removed and the pellet resuspended in 1% BSA (w/v) in PBS and incubated on ice for 1 h. The cells were washed three times with PBS and then resuspended in 100 jil of antibody solutions and incubated on ice for 1 h. After three washes in PBS, secondary antibodies were applied to each sample. Samples with murine antibodies as the primary layer were treated with rabbit anti-mouse Ig/FITC-conjugated antibodies (Dako, High Wycombe, UK) (100 jl of a 1:500 dilution in PBS). Samples containing C595 scFv were incubated with an equal amount of a mouse anti-E-Tag antibody (Pharmacia) for 1 h on ice, washed four times in PBS and incubated in a solution of the rabbit antimouse Ig/FITC-conjugated antibody (Dako) as described above. Samples were then washed four times in PBS and fixed in 1 ml of 0.5% formaldehyde (v/v) in PBS and analysed by FACScan (Becton Dickinson). Relative fluorescence values were calculated according to Schmid et al (1988) .
Immunoreactivity with synthetic MUC1 peptide C595, C595 scFv and an irrelevant IgG molecule, the anti-MUC2 monoclonal 996 (100 jil at 10 jig ml-'), were added to 1:5 (v/v) suspensions of 4B-CL Sepharose beads (0.5 ml) both with and without peptide (CAPDTRPAPG) conjugated to them. Incubations of antibody and fragments with the Sepharose beads were performed as described for incubations with the cells by FACScan analysis. After the appropriate secondary antibody layers had been added and the beads washed in PBS, ABTS substrate solution was added to the beads as described in the ELISA procedure (100 jl per sample). The beads were centrifuged and the ABTS supernatant added to a 96-well microtitre plate for end point analysis on the Milenia Kinetic Analyser. Samples were analysed in triplicate.
Immunohistochemistry
Sequential 3-jim sections were cut from archival paraffin blocks of breast and transitional cell bladder tumours, dewaxed in xylene and rehydrated in graded alcoholic solutions. Endogenous peroxidase activity was blocked with 1% hydrogen peroxide in methanol for 10 min. Non-specific binding was blocked with normal swine serum diluted 1:10 for 10 min. Immunostaining was performed using a semiautomated immunostainer (Shandon Sequenza). The primary antibody was applied for 1 h. To detect scFv binding, specimens were incubated for 1 h with mouse anti-E-Tag (1:50) in PBS. Optimal antibody concentrations were determined by titration. Detection of antibody binding was performed using biotinylated goat anti-mouse/rabbit immunoglobulins followed by streptavidin/biotinylated horseradish peroxidase complex (Dako, StreptABC complex/HRP duet, mouse/rabbit). Staining was performed by addition of 0.025% diaminobenzidine (Sigma) diluted in 0.1 M Tris buffer (pH 7.6), with hydrogen peroxide as the substrate. Tissue sections were counterstained with haematoxylin, then rehydrated in graded alcohol solutions, cleared in xylene and mounted in DPX mountant. Negative controls were performed by omitting the primary antibody. Immunostaining was performed without any form of antigen retrieval.
Fluorescence quenching Fluorescence quenching experiments were performed using both C595 and C595 scFv against MUCI protein core-related peptides. C595 antibody was diluted in PBS to a concentration of 0.12 jM and C595 scFv diluted likewise to a concentration of 0.27 jM. Peptides were diluted to 60 jM. The antibody and fragment solutions (2.5 ml) were filtered through a 0.2-jim membrane filter unit (Sartorius, Gottingen, Germany) and 2 ml of these solutions British Joumal of Cancer (1997) 76(5), [614] [615] [616] [617] [618] [619] [620] [621] 0 Cancer Research Campaign 1997 scFv against MUC1 mucin 617 Figure 1 Agarose gel of PCR products obtained from C595 scFv phagemid library-infected HB2151 clones. Upper lanes contain PCR products from clones using Si and S6 primers and lower lanes contain PCR products from clones using 11 and 12 primers. In both cases, lane 1 contains molecular weight standards of 2000, 1500, 1000, 750, 500, 300, 150 and 50 bp (Sigma). Lanes 2-7 contain DNA amplified from clones 3, 17, 22, 31, 69 and 72 respectively pipetted into a 3-ml quartz cuvette (1-cm pathlength). The solution was excited at 290 nm and emitted light monitored at 345 nm using a Luminescence Spectrometer LS-5 (Perkin Elmer). Aliquots (2.5 jl) of the peptide solutions were added to the antibody or fragment solutions until maximum fluorescence quenching was observed. Calculations were performed according to the method of Eisen (1964) 
RESULTS

C595 scFv assembly and expression
Insertion of C595 VH_ and VL-specific DNA in the scFv assembly process was analysed by PCR amplification of the DNA from phagemid-infected HB2151 E. coli clones grown on ampicillin plates. These tests were performed using plasmid (phagemid)-specific primers SI and S6 and C595-specific primers II and 12.
Analysis using the SI and S6 primers in a number of clones confirmed the insertion of DNA in the Sfi1 and Not! cloning site.
These clones (numbered 3, 17, 22, 31 and 69) produced PCR products of approximately 950 bp in length (Figure 1, upper panel) . The size of these products is consistent with the assembly of linked VH and VL into the phagemid vector at the SfiI and Not! cloning site. Infection of the ligated phagemid into HB2151 E. coli was also reported by the presence of C595-specific DNA in these clones using the II and I2 primers (Figure 1, lower panel) . Here, clones containing the C595 scFv-encoding DNA produce PCR products of approximately 400 bp, which is consistent with the assembly of linked VH and VL into the phagemid vector in the correct orientation.
All clones generating PCR products of a size not consistent with the insertion of linked VH_ and VL-encoding DNA (the example given in Figure 1 is clone 72) with SI and S6 primers failed to produce PCR products from reactions containing II and I2 This clone was further analysed by DNA sequencing techniques using the primers S1, S6, I1 and I2 to identify the exact DNA sequence of the inserted C595 scFv-encoding region. Table 1 presents the translated primary sequence of the C595 scFv clone 31 and compares the relevant portions of the assembled recombinant fragment with those of the parent antibody . The portions of the scFv representing the variable regions are homologous with parental antibody sequences except for five conservative changes. These differences reflect the degenerate nature of the primers used in the RPAS PCRs and the fact that primers with sequences that are not exactly complementary are Relative fluorescence Figure 6 FACScan analysis of the binding of C595 and C595 scFv to T47D cells. w6/32 is an anti-HLA-ABC positive control antibody, whereas 996 is a MUC2-specific negative control antibody. Cells alone have no antibodies added to the cells, and FITC and E-Tag+FITC represent the addition of these antibodies as appropriate negative controls for C595 and C595 scFv respectively able to anneal to the cDNA template and prime the PCR. No differences occur within the CDRs of the C595 scFv when compared with the C595 sequence.
Purification of C595 scFv clone 31
The production of C595 scFv clone 31 was scaled up from 50 ml per sample to 800 ml per sample for purification of the antibody fragment by peptide epitope affinity chromatography. Fractions of column eluent were collected as described and the scFv in the eluent was quantified spectrophotometrically from UV absorbance at 280 nm. Appropriate fractions were further analysed by SDS-PAGE and Western blotting (Figure 2 ). Lanes (a) and (b) in Figure 2 Figure 4B) . Clearly, the scFv is able to bind to the peptide CAPDTRAPAPG.
Fluorescence quenching
The results of fluorescence quenching experiments are given in Figure 5 . Scatchard analysis of C595 and C595 scFv reveal that both whole and antibody fragments possess the capacity to bind to different Immunohistochemistry Figure 7A and B shows the ability of both C595 and C595 scFv to preferentially bind to breast tumour tissue sections. The cytoplasmic and surface staining pattern is characteristic of the expression of MUCI mucins as described by Zotter et al (1988) . Some weak staining to benign breast ducts using the whole antibody is seen in Figure 7A but is not observed for the scFv ( Figure 7B ).
DISCUSSION
The results presented here confirm the successful production of a recombinant single-chain antibody fragment (scFv) retaining the capacity to bind to MUCI mucin. Assembly of scFv, using the antibody variable region genes and the recombinant antibody phage system as described, produces a recombinant protein in which the structural features that define the fine specificity of the parent antibody for its antigen are retained. The only observed differences in primary structure between the parent and recombinant variable regions occur at the priming sites for the antibody genes (Table 1) . These reflect the presence of a degenerate primer mixture used in the RPAS to amplify genes from many V region gene families. The variation from the parental in the C595 scFv clone 31 is conservative and does not occur in the complementarity determining regions. These framework substitutions have no significant effect on antibody binding, nor does the incorporation of the (G4S)3 linker sequence and the reporter (E-Tag) sequence at the C-terminus. The ability to produce recombinant C595 scFv from this vector system should afford analyses of how point mutations in the CDRs affect antigen/antibody interactions, with particular emphasis on the CDR H3. Use of these manipulations and the ability to rapidly analyse their effects on peptide antigen systems should give valuable information on how these antibodies recognize tumour cells, and these experiments are currently underway.
Analysis by FACScan and immunohistochemistry report the ability of the scFv to bind to tumour cells. Immunohistochemical analysis of the binding of scFv by these methods does not indicate binding of this molecule to benign breast ducts, an observation seen with the whole antibody. This may afford the preferential use of the scFv over the C595 whole antibody as a diagnostic agent. However, further immunohistochemical analyses are required to test this proposal and these investigations are being pursued. Similar staining patterns were obtained with sections from bladder carcinomas.
Fluorescence quenching (FQ) experiments indicate the capacity of the scFv to bind to MUC1 and different MUC1-related peptides. FQ analysis is sufficient to observe the general binding trends of these antibodies and fragments to peptides in solution. Techniques such as surface plasmon resonance may be used in future experiments to investigate binding constants of these antibodies and fragments on immobilized antigens and would serve to confirm the binding trends observed with FQ. From the experimental data presented, it is interesting to note the possible effect of avidity on the binding capacities of these reagents as observed in the multiple epitopic peptide antigens (60 and 105 mer). This may indicate that a recombinant bivalent scFv (diabody) may prove to be a useful reagent in a diagnostic scenario, and the production of such a molecule is currently being pursued. However, a low-affinity reagent may also be of some use as affinity influences the penetration of these reagents into solid tumours. This property allied to the reduced size of the scFv and the penetrative advantage that this gives (Yokota et al, 1992 ) may be of benefit in the treatment of more substantial tumours.
Experiments have been performed in which intravesicular administration of "'In-labelled C595 in patients with superficial bladder cancer resulted in the selective accumulation of the antibody in the tumour with a mean tumour-normal selectivity ratio of 12:1 after 2 h. Administration of whole mouse antibody by this route has been shown not to produce human anti-murine antibody (HAMA) responses in patients even after multiple administrations (Kunkler et al, 1995) . These findings establish the basis for extending the clinical usage of anti-MUCI monoclonal antibodies as targeting agents with anti-tumour activity. A clinical trial is presently underway to examine tumour targeting of 67Cu-labelled C595 following intravesical administration in patients with superficial bladder cancer (Hughes et al, 1997) . This radionuclide emits both gamma and beta radioactivity and thus has potential use for both diagnosis and radioimmunotherapy. The increased tumour penetrative properties that C595 scFv may offer is presently being examined. scFv to replace the whole antibody would be the decrease in immunogenicity of the fragment over the parent molecule as well as the pharmacokinetic advantage of using a smaller molecule that has increased blood clearance times. Although still of murine origin, a decrease in immunogenicity may allow multiple therapeutic doses to be administered, an obvious advantages in patient management.
In summary, recombinant C595 scFv retains the ability to bind to tumour cells, MUCI antigen and synthetic MUCI peptides. This reagent, therefore, has diagnostic and therapeutic potential. It may further prove to be a valuable tool in probing the fine specificity of antibody recognition on MUC1-positive tumour cells, leading to a greater understanding of the immune recognition of cancer cells.
